These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 24427314)

  • 1. Gene and MicroRNA transcriptome analysis of Parkinson's related LRRK2 mouse models.
    Dorval V; Mandemakers W; Jolivette F; Coudert L; Mazroui R; De Strooper B; Hébert SS
    PLoS One; 2014; 9(1):e85510. PubMed ID: 24427314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homozygous mutation of the LRRK2 ROC domain as a novel genetic model of parkinsonism.
    Chen ML; Wu RM
    J Biomed Sci; 2022 Aug; 29(1):60. PubMed ID: 35965315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-205 regulates the expression of Parkinson's disease-related leucine-rich repeat kinase 2 protein.
    Cho HJ; Liu G; Jin SM; Parisiadou L; Xie C; Yu J; Sun L; Ma B; Ding J; Vancraenenbroeck R; Lobbestael E; Baekelandt V; Taymans JM; He P; Troncoso JC; Shen Y; Cai H
    Hum Mol Genet; 2013 Feb; 22(3):608-20. PubMed ID: 23125283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The parkinson's disease-associated LRRK2 mutation R1441G inhibits neuronal differentiation of neural stem cells.
    Bahnassawy L; Nicklas S; Palm T; Menzl I; Birzele F; Gillardon F; Schwamborn JC
    Stem Cells Dev; 2013 Sep; 22(18):2487-96. PubMed ID: 23600457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using Extracellular miRNA Signatures to Identify Patients with LRRK2-Related Parkinson's Disease.
    Braunger LJ; Knab F; Gasser T
    J Parkinsons Dis; 2024; 14(5):977-991. PubMed ID: 38848197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-variance RNAs identify Parkinson's disease molecular signature in blood.
    Chikina MD; Gerald CP; Li X; Ge Y; Pincas H; Nair VD; Wong AK; Krishnan A; Troyanskaya OG; Raymond D; Saunders-Pullman R; Bressman SB; Yue Z; Sealfon SC
    Mov Disord; 2015 May; 30(6):813-21. PubMed ID: 25786808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptional responses to loss or gain of function of the leucine-rich repeat kinase 2 (LRRK2) gene uncover biological processes modulated by LRRK2 activity.
    Nikonova EV; Xiong Y; Tanis KQ; Dawson VL; Vogel RL; Finney EM; Stone DJ; Reynolds IJ; Kern JT; Dawson TM
    Hum Mol Genet; 2012 Jan; 21(1):163-74. PubMed ID: 21972245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of blood serum micro-RNAs associated with idiopathic and LRRK2 Parkinson's disease.
    Botta-Orfila T; Morató X; Compta Y; Lozano JJ; Falgàs N; Valldeoriola F; Pont-Sunyer C; Vilas D; Mengual L; Fernández M; Molinuevo JL; Antonell A; Martí MJ; Fernández-Santiago R; Ezquerra M
    J Neurosci Res; 2014 Aug; 92(8):1071-7. PubMed ID: 24648008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression.
    Gehrke S; Imai Y; Sokol N; Lu B
    Nature; 2010 Jul; 466(7306):637-41. PubMed ID: 20671708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diapocynin prevents early Parkinson's disease symptoms in the leucine-rich repeat kinase 2 (LRRK2R¹⁴⁴¹G) transgenic mouse.
    Dranka BP; Gifford A; Ghosh A; Zielonka J; Joseph J; Kanthasamy AG; Kalyanaraman B
    Neurosci Lett; 2013 Aug; 549():57-62. PubMed ID: 23721786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parkinson's disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity.
    Gillardon F; Schmid R; Draheim H
    Neuroscience; 2012 Apr; 208():41-8. PubMed ID: 22342962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel mitochondrially-targeted apocynin derivative prevents hyposmia and loss of motor function in the leucine-rich repeat kinase 2 (LRRK2(R1441G)) transgenic mouse model of Parkinson's disease.
    Dranka BP; Gifford A; McAllister D; Zielonka J; Joseph J; O'Hara CL; Stucky CL; Kanthasamy AG; Kalyanaraman B
    Neurosci Lett; 2014 Nov; 583():159-64. PubMed ID: 25263790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An early axonopathy in a hLRRK2(R1441G) transgenic model of Parkinson disease.
    Tagliaferro P; Kareva T; Oo TF; Yarygina O; Kholodilov N; Burke RE
    Neurobiol Dis; 2015 Oct; 82():359-371. PubMed ID: 26192625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S.
    Li X; Patel JC; Wang J; Avshalumov MV; Nicholson C; Buxbaum JD; Elder GA; Rice ME; Yue Z
    J Neurosci; 2010 Feb; 30(5):1788-97. PubMed ID: 20130188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2-G2019S Mutation.
    Matikainen-Ankney BA; Kezunovic N; Mesias RE; Tian Y; Williams FM; Huntley GW; Benson DL
    J Neurosci; 2016 Jul; 36(27):7128-41. PubMed ID: 27383589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypothesis: Do miRNAs Targeting the Leucine-Rich Repeat Kinase 2 Gene (LRRK2) Influence Parkinson's Disease Susceptibility?
    Yılmaz ŞG; Geyik S; Neyal AM; Soko ND; Bozkurt H; Dandara C
    OMICS; 2016 Apr; 20(4):224-8. PubMed ID: 27093107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression.
    Henry AG; Aghamohammadzadeh S; Samaroo H; Chen Y; Mou K; Needle E; Hirst WD
    Hum Mol Genet; 2015 Nov; 24(21):6013-28. PubMed ID: 26251043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive and behavioral symptoms in Parkinson's disease patients with the G2019S and R1441G mutations of the LRRK2 gene.
    Somme JH; Molano Salazar A; Gonzalez A; Tijero B; Berganzo K; Lezcano E; Fernandez Martinez M; Zarranz JJ; Gómez-Esteban JC
    Parkinsonism Relat Disord; 2015 May; 21(5):494-9. PubMed ID: 25840672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-motor and motor features in LRRK2 transgenic mice.
    Bichler Z; Lim HC; Zeng L; Tan EK
    PLoS One; 2013; 8(7):e70249. PubMed ID: 23936174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The mouse/human cross-species heterodimer of leucine-rich repeat kinase 2: possible significance in the transgenic model mouse of Parkinson's disease.
    Miyajima T; Ohta E; Kawada H; Maekawa T; Obata F
    Neurosci Lett; 2015 Feb; 588():142-6. PubMed ID: 25562633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.